menu
    • menu
    [{"orgOrder":0,"company":"Ambrx Inc","sponsor":"Fidelity Management & Research Company","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Large molecule","year":"2020","type":"Financing","leadProduct":"ARX788","moa":"HER2","graph1":"Oncology","graph2":"Phase I","graph3":"Ambrx Inc","amount2":0.20000000000000001,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0.20000000000000001,"dosageForm":"","sponsorNew":"Ambrx Inc \/ Fidelity Management & Research Company","highestDevelopmentStatusID":"6","companyTruncated":"Ambrx Inc \/ Fidelity Management & Research Company"},{"orgOrder":0,"company":"Ambrx Inc","sponsor":"NovoCodex","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"ARX788","moa":"HER2","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Ambrx Inc","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"intravenous infusion","sponsorNew":"Ambrx Inc \/ NovoCodex","highestDevelopmentStatusID":"9","companyTruncated":"Ambrx Inc \/ NovoCodex"},{"orgOrder":0,"company":"Ambrx Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Large molecule","year":"2021","type":"Not Applicable","leadProduct":"ARX788","moa":"Tubulin","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Ambrx Inc","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous infusion","sponsorNew":"Ambrx Inc \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Ambrx Inc \/ Not Applicable"},{"orgOrder":0,"company":"Ambrx Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Large molecule","year":"2021","type":"Not Applicable","leadProduct":"ARX788","moa":"Tubulin","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Ambrx Inc","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous infusion","sponsorNew":"Ambrx Inc \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Ambrx Inc \/ Not Applicable"},{"orgOrder":0,"company":"Ambrx Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Large molecule","year":"2021","type":"Not Applicable","leadProduct":"ARX788","moa":"Tubulin","graph1":"Oncology","graph2":"Phase II","graph3":"Ambrx Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Ambrx Inc \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Ambrx Inc \/ Not Applicable"},{"orgOrder":0,"company":"Ambrx Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Large molecule","year":"2021","type":"Not Applicable","leadProduct":"ARX788","moa":"Tubulin","graph1":"Oncology","graph2":"Phase II","graph3":"Ambrx Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Ambrx Inc \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Ambrx Inc \/ Not Applicable"},{"orgOrder":0,"company":"Ambrx Inc","sponsor":"Quantum Leap Healthcare","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"ARX788","moa":"Tubulin","graph1":"Oncology","graph2":"Phase II","graph3":"Ambrx Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Ambrx Inc \/ Quantum Leap Healthcare","highestDevelopmentStatusID":"8","companyTruncated":"Ambrx Inc \/ Quantum Leap Healthcare"},{"orgOrder":0,"company":"Ambrx Inc","sponsor":"Zhejiang Medicine Co Ltd","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Large molecule","year":"2022","type":"Agreement","leadProduct":"ARX305","moa":"CD70","graph1":"Oncology","graph2":"Phase I","graph3":"Ambrx Inc","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Ambrx Inc \/ NovoCodex","highestDevelopmentStatusID":"6","companyTruncated":"Ambrx Inc \/ NovoCodex"},{"orgOrder":0,"company":"Ambrx Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"ARX788","moa":"","graph1":"Oncology","graph2":"Phase II","graph3":"Ambrx Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Ambrx Inc \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Ambrx Inc \/ Not Applicable"},{"orgOrder":0,"company":"Ambrx Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"ARX788","moa":"","graph1":"Oncology","graph2":"Phase II","graph3":"Ambrx Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Ambrx Inc \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Ambrx Inc \/ Not Applicable"},{"orgOrder":0,"company":"Ambrx Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Large molecule","year":"2023","type":"Not Applicable","leadProduct":"ARX517","moa":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Ambrx Inc","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Ambrx Inc \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Ambrx Inc \/ Not Applicable"},{"orgOrder":0,"company":"Ambrx Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Large molecule","year":"2023","type":"Not Applicable","leadProduct":"ARX788","moa":"","graph1":"Oncology","graph2":"Phase II","graph3":"Ambrx Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Ambrx Inc \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Ambrx Inc \/ Not Applicable"},{"orgOrder":0,"company":"Ambrx Inc","sponsor":"Cowen and Company LLC","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Large molecule","year":"2023","type":"Public Offering","leadProduct":"ARX788","moa":"","graph1":"Oncology","graph2":"Phase II","graph3":"Ambrx Inc","amount2":0.080000000000000002,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0.080000000000000002,"dosageForm":"Infusion","sponsorNew":"Ambrx Inc \/ Cowen and Company LLC","highestDevelopmentStatusID":"8","companyTruncated":"Ambrx Inc \/ Cowen and Company LLC"},{"orgOrder":0,"company":"Ambrx Inc","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Large molecule","year":"2023","type":"Public Offering","leadProduct":"ARX788","moa":"","graph1":"Oncology","graph2":"Phase II","graph3":"Ambrx Inc","amount2":0.080000000000000002,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0.080000000000000002,"dosageForm":"Infusion","sponsorNew":"Ambrx Inc \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Ambrx Inc \/ Undisclosed"},{"orgOrder":0,"company":"Ambrx Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Large molecule","year":"2023","type":"Not Applicable","leadProduct":"ARX517","moa":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Ambrx Inc","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Ambrx Inc \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Ambrx Inc \/ Not Applicable"},{"orgOrder":0,"company":"Ambrx Inc","sponsor":"Johnson & Johnson","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Large molecule","year":"2024","type":"Acquisition","leadProduct":"ARX517","moa":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Ambrx Inc","amount2":2,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":2,"dosageForm":"Infusion","sponsorNew":"Ambrx Inc \/ Johnson & Johnson","highestDevelopmentStatusID":"7","companyTruncated":"Ambrx Inc \/ Johnson & Johnson"},{"orgOrder":0,"company":"Ambrx Inc","sponsor":"Johnson & Johnson","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Large molecule","year":"2024","type":"Acquisition","leadProduct":"ARX517","moa":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Ambrx Inc","amount2":2,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":2,"dosageForm":"Infusion","sponsorNew":"Ambrx Inc \/ Johnson & Johnson","highestDevelopmentStatusID":"7","companyTruncated":"Ambrx Inc \/ Johnson & Johnson"},{"orgOrder":0,"company":"Ambrx Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Large molecule","year":"2023","type":"Not Applicable","leadProduct":"ARX517","moa":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Ambrx Inc","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Ambrx Inc \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Ambrx Inc \/ Not Applicable"}]

    Find Clinical Drug Pipeline Developments & Deals by Ambrx Inc

    Menu

    Ambrx Inc

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Ambrx Inc

                            U.S.A arrow
                            Antibody Engineering
                            Not Confirmed

                            Ambrx Inc

                            U.S.A arrow
                            Antibody Engineering
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : ARX517

                            Therapeutic Area : Oncology

                            Study Phase : Phase I/ Phase II

                            Sponsor : Johnson & Johnson

                            Deal Size : $2,000.0 million

                            Deal Type : Acquisition

                            DEALS_DEV arrow-down

                            Johnson & Johnson Completes Acquisition of Ambrx

                            Details : The acquisition allows Johnson to focus on developing ARX517, a PSMA inhibitor ADC currently evaluated in clinical trials for treating metastatic castration-resistant prostate cancer.

                            Brand Name : ARX517

                            Molecule Type : Large molecule

                            Upfront Cash : Undisclosed

                            March 07, 2024

                            Lead Product(s) : ARX517

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Johnson & Johnson

                            Deal Size : $2,000.0 million

                            Deal Type : Acquisition

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Ambrx Inc

                            U.S.A arrow
                            Antibody Engineering
                            Not Confirmed

                            Ambrx Inc

                            U.S.A arrow
                            Antibody Engineering
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : ARX517

                            Therapeutic Area : Oncology

                            Study Phase : Phase I/ Phase II

                            Sponsor : Johnson & Johnson

                            Deal Size : $2,000.0 million

                            Deal Type : Acquisition

                            DEALS_DEV arrow-down

                            Johnson & Johnson to Acquire Ambrx for Next-Generation Antibody Conjugates

                            Details : Johnson's acquisition will expand its ADC portfolio, adding ARX517 for mCRPC, ARX788 for HER2+ breast cancer, and ARX305 for renal cell carcinoma.

                            Brand Name : ARX517

                            Molecule Type : Large molecule

                            Upfront Cash : $1,900.0 million

                            January 08, 2024

                            Lead Product(s) : ARX517

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Johnson & Johnson

                            Deal Size : $2,000.0 million

                            Deal Type : Acquisition

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Ambrx Inc

                            U.S.A arrow
                            Antibody Engineering
                            Not Confirmed

                            Ambrx Inc

                            U.S.A arrow
                            Antibody Engineering
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : ARX517

                            Therapeutic Area : Oncology

                            Study Phase : Phase I/ Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Ambrx Provides Update On APEX-01, an On-Going Phase 1 / 2 Dose Escalation Study Evaluating ARX517, a Proprieta...

                            Details : ARX517 is an investigational antibody-drug conjugate composed of a humanized anti-PSMA mAb linked to AS269, an Ambrx proprietary potent microtubule inhibitor. It is being evaluated for the treatment of metastatic castration-resistant prostate cancer.

                            Brand Name : ARX517

                            Molecule Type : Large molecule

                            Upfront Cash : Not Applicable

                            November 28, 2023

                            Lead Product(s) : ARX517

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Ambrx Inc

                            U.S.A arrow
                            Antibody Engineering
                            Not Confirmed

                            Ambrx Inc

                            U.S.A arrow
                            Antibody Engineering
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : ARX517

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            FDA Grants Fast Track Designation for Ambrx™s ARX517 for the Treatment of Metastatic Castration-Resistant Pr...

                            Details : ARX517 is an antibody-drug conjugate composed of a fully humanized anti-PSMA mAb linked to AS269, a potent microtubule inhibitor. It is being investigated for metastatic castration-resistant prostate cancer.

                            Brand Name : ARX517

                            Molecule Type : Large molecule

                            Upfront Cash : Not Applicable

                            July 19, 2023

                            Lead Product(s) : ARX517

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Ambrx Inc

                            U.S.A arrow
                            Antibody Engineering
                            Not Confirmed

                            Ambrx Inc

                            U.S.A arrow
                            Antibody Engineering
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : ARX788,Capecitabine,Lapatinib Ditosylate

                            Therapeutic Area : Oncology

                            Study Phase : Phase II

                            Sponsor : Undisclosed

                            Deal Size : $75.0 million

                            Deal Type : Public Offering

                            DEALS_DEV arrow-down

                            Ambrx Announces Closing of $75 Million Market Priced Registered Offering

                            Details : The Company intends to use the net proceeds to fund the research and development of its product candidates, including ARX788, a next-generation, site-specific anti-HER2 ADC, being developed for the treatment of HER2-positive metastatic breast cancer.

                            Brand Name : ARX788

                            Molecule Type : Large molecule

                            Upfront Cash : Undisclosed

                            June 28, 2023

                            Lead Product(s) : ARX788,Capecitabine,Lapatinib Ditosylate

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase II

                            Sponsor : Undisclosed

                            Deal Size : $75.0 million

                            Deal Type : Public Offering

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Ambrx Inc

                            U.S.A arrow
                            Antibody Engineering
                            Not Confirmed

                            Ambrx Inc

                            U.S.A arrow
                            Antibody Engineering
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : ARX788

                            Therapeutic Area : Oncology

                            Study Phase : Phase II

                            Sponsor : Cowen and Company LLC

                            Deal Size : $80.0 million

                            Deal Type : Public Offering

                            DEALS_DEV arrow-down

                            Ambrx Raises $78 Million and Completes its ATM Program

                            Details : The financing will be used in the advancement of ARX788 and ARX517. ARX788 is an antibody drug conjugate (ADC) consisting of a humanized anti-HER2 monoclonal antibody (mAb) covalently conjugated to two microtubule-disrupting payloads AS269.

                            Brand Name : ARX788

                            Molecule Type : Large molecule

                            Upfront Cash : Undisclosed

                            March 13, 2023

                            Lead Product(s) : ARX788

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase II

                            Sponsor : Cowen and Company LLC

                            Deal Size : $80.0 million

                            Deal Type : Public Offering

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Ambrx Inc

                            U.S.A arrow
                            Antibody Engineering
                            Not Confirmed

                            Ambrx Inc

                            U.S.A arrow
                            Antibody Engineering
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : ARX788,Capecitabine,Lapatinib Ditosylate

                            Therapeutic Area : Oncology

                            Study Phase : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            ACE-Breast-02 Pivotal Phase 3 Study of Ambrx’s ARX788 for the Treatment of HER2 Positive Metastatic Breast C...

                            Details : ARX788, an anti-HER2 antibody drug conjugate currently being studied broadly in breast cancer, gastric/GEJ cancer and other solid tumor clinical trials.

                            Brand Name : ARX788

                            Molecule Type : Large molecule

                            Upfront Cash : Not Applicable

                            March 01, 2023

                            Lead Product(s) : ARX788,Capecitabine,Lapatinib Ditosylate

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            Ambrx Inc

                            U.S.A arrow
                            Antibody Engineering
                            Not Confirmed

                            Ambrx Inc

                            U.S.A arrow
                            Antibody Engineering
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : ARX517

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            ARX517, Ambrx’s Proprietary Anti-PSMA ADC, Shows Encouraging Single-Agent Safety and Efficacy Data in Patien...

                            Details : ARX517 is an antibody-drug conjugate composed of a fully humanized anti-PSMA mAb linked to AS269, a potent microtubule inhibitor. It is being investigated for metastatic castration-resistant prostate cancer.

                            Brand Name : ARX517

                            Molecule Type : Large molecule

                            Upfront Cash : Not Applicable

                            February 16, 2023

                            Lead Product(s) : ARX517

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            Ambrx Inc

                            U.S.A arrow
                            Antibody Engineering
                            Not Confirmed

                            Ambrx Inc

                            U.S.A arrow
                            Antibody Engineering
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : ARX788

                            Therapeutic Area : Oncology

                            Study Phase : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Ambrx Announces Encouraging Preliminary Safety and Efficacy Data Evaluating ARX788 in HER2 Positive Metastatic...

                            Details : ARX788, an anti-HER2 ADC being evaluated for patients whose metastatic disease is resistant or refractory to T-DXd, T-DM1, or tucatinib-containing regimens.

                            Brand Name : ARX788

                            Molecule Type : Large molecule

                            Upfront Cash : Not Applicable

                            December 09, 2022

                            Lead Product(s) : ARX788

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            10

                            Ambrx Inc

                            U.S.A arrow
                            Antibody Engineering
                            Not Confirmed

                            Ambrx Inc

                            U.S.A arrow
                            Antibody Engineering
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : ARX788

                            Therapeutic Area : Oncology

                            Study Phase : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Interim Data from Ambrx’s Study of ARX788 Selected for Spotlight Poster Discussion at the 2022 San Antonio B...

                            Details : ARX788 is an anti-HER2 antibody drug conjugate currently being studied in several registrational trials in breast cancer and gastric/GEJ cancer in patients with HER2+ mBC) whose disease progressed following T-DM1, T-DXd and/or tucatinib-containing regime...

                            Brand Name : ARX788

                            Molecule Type : Large molecule

                            Upfront Cash : Not Applicable

                            November 29, 2022

                            Lead Product(s) : ARX788

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth